AJU IB Investment Co. Ltd. Sells 437,411 Shares of Kymera Therapeutics, Inc. $KYMR

Key Points

• AJU IB Investment Co. Ltd. sharply reduced its Kymera Therapeutics stake by 95.7% in the fourth quarter, selling 437,411 shares and leaving it with 19,648 shares worth about $1.53 million.
• Kymera Therapeutics posted better-than-expected first-quarter results, with EPS of ($0.71) versus estimates of ($0.89) and revenue of $34.37 million, well above the $8.27 million forecast.
• Analysts remain largely upbeat on the stock, with a consensus rating of Moderate Buy and an average price target of $118.10, while the shares recently traded around $81.46.

AJU IB Investment Co. Ltd. decreased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 95.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,648 shares of the company's stock after selling 437,411 shares during the quarter. Kymera Therapeutics comprises approximately 8.0% of AJU IB Investment Co. Ltd.'s investment portfolio, making the stock its 2nd biggest position. AJU IB Investment Co. Ltd.'s holdings in Kymera Therapeutics were worth $1,529,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. US Bancorp DE lifted its stake in Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company's stock worth $106,000 after purchasing an additional 166 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Kymera Therapeutics by 9.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company's stock worth $156,000 after buying an additional 248 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company's stock worth $83,000 after buying an additional 287 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Kymera Therapeutics by 2.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 30,573 shares of the company's stock worth $2,379,000 after buying an additional 645 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Kymera Therapeutics by 5.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,631 shares of the company's stock worth $1,216,000 after buying an additional 789 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KYMR. Citigroup increased their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the company a "buy" rating in a report on Monday, March 2nd. Royal Bank Of Canada restated an "outperform" rating and issued a $108.00 price objective on shares of Kymera Therapeutics in a report on Thursday, February 26th. Canaccord Genuity Group initiated coverage on Kymera Therapeutics in a report on Wednesday, May 6th. They issued a "buy" rating and a $106.00 price objective for the company. Jefferies Financial Group initiated coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a "buy" rating and a $110.00 price objective for the company. Finally, UBS Group increased their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the company a "buy" rating in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $118.10.

Kymera Therapeutics Stock Down 0.3%

Kymera Therapeutics stock opened at $81.46 on Friday. Kymera Therapeutics, Inc. has a 52 week low of $28.50 and a 52 week high of $103.00. The company's 50 day moving average price is $83.29 and its two-hundred day moving average price is $79.30. The stock has a market cap of $6.70 billion, a P/E ratio of -22.82 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analysts' expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company's quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.82) EPS. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.34 EPS for the current year.

Insider Activity

In related news, insider Noah Goodman sold 8,264 shares of the company's stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $87.50, for a total value of $723,100.00. Following the completion of the transaction, the insider directly owned 53,542 shares in the company, valued at approximately $4,684,925. The trade was a 13.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Bruce N. Jacobs sold 7,576 shares of the company's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $88.93, for a total transaction of $673,733.68. Following the completion of the transaction, the chief financial officer owned 237,483 shares of the company's stock, valued at $21,119,363.19. This trade represents a 3.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 370,918 shares of company stock worth $31,120,324. Company insiders own 15.98% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.